Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Receivables (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Receivables over the past 15 years, most recently at $20.5 million for Q2 2025.

  • Quarterly results put Receivables at $20.5 million for Q2 2025, up 37.89% from a year ago — trailing twelve months through May 2025 was $20.5 million (up 37.89% YoY), and the annual figure for FY2025 was $20.5 million, down 41.75%.
  • Receivables for Q2 2025 was $20.5 million at Lifecore Biomedical, Inc. \De\, up from $17.5 million in the prior quarter.
  • Over the last five years, Receivables for LFCR hit a ceiling of $53.6 million in Q1 2022 and a floor of $14.9 million in Q2 2024.
  • Median Receivables over the past 5 years was $33.9 million (2023), compared with a mean of $31.5 million.
  • Biggest five-year swings in Receivables: crashed 66.71% in 2023 and later soared 96.56% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Receivables stood at $40.1 million in 2021, then decreased by 10.57% to $35.9 million in 2022, then tumbled by 37.72% to $22.3 million in 2023, then skyrocketed by 61.22% to $36.0 million in 2024, then tumbled by 43.01% to $20.5 million in 2025.
  • The last three reported values for Receivables were $20.5 million (Q2 2025), $17.5 million (Q1 2025), and $36.0 million (Q4 2024) per Business Quant data.